Nimbus Therapeutics

Mark is a healthcare executive with more than 20 years of experience. Leone-Bay is an internationally recognized authority on inhaled dry powder and oral drug delivery technologies. Kraft has over 20 years of pharmaceutical industry experience in oral and inhaled drug delivery. Kraft leads Receptor's product development team from basic research through manufacturing, testing, release, and stability of Phase 1 clinical supplies. Weissman leads alliance management, business development, corporate communications, corporate operations, and new product planning. Weissman was vice president of business development at MannKind Corporation, responsible for leading the company’s activities related to licensing, new products and strategic planning. Warren Lammert has over 35 years of public and private investment experience and is the founder and Co-Chief Investment Officer of Granite Point Capital, a Boston-based investment firm with over $300 million in assets that invests in both public and private companies. Prior to Antios, Mayes founded Engage Therapeutics and served as the company’s President and CEO.

We are a start-up originally spun out of Dr. Dhivya is a passionate Entrepreneur with 15+ years experience in defining winning strategies and building high performance teams. Vergara has 14+ years of experience in experimental and computational biology. Shellard has a PhD and 12+ years of experience in cell biology and live imaging. Brian brings a track record of leading teams to deliver transformative results for clients across the healthcare sector at McKinsey and Company with particular focus on strategy / corporate finance, go-to-market, and M&A. Laghrissi is the CEO of DalCor Pharmaceuticals and has more than 20 years of pharmaceutical industry leadership experience, including roles at AstraZeneca, Roche, HBA and WPIC. Kupfer is the ex-Head of the DSM-5 plan committee, and has expert knowledge of the current principal manual for psychiatric & neurocognitive diagnosis, as recommended by the American Psychiatric Association. Linder is the CEO at Calciscon AG, biomedical consultant, entrepreneur & senior biotech executive with track record of success for biomedical devices.

Ahmad is a trained internist and clinical oncologist and brings over two decades of successful strategic clinical development, medical affairs, and marketing authorization expertise. Zocca brings more than 18 years of experience in the biotechnology field and has participated in the founding and co-founding of several biotech spinouts. Sullivan is a seasoned life sciences professional with more than 25 years of experience raising capital and building and managing corporate biotechnology and life sciences brands. Faulkner brings more than 25 years of technical operations, quality, and product launch experience within the biotechnology industry. Faulkner has experience in product development, manufacturing operations, supply chain, and commercialization of peptides, proteins, monoclonal antibodies, viruses, and combination products. Faulkner held senior roles at Homology Medicines as head of CMC management and external manufacturing, product operations lead for the Rare Disease Business Unit at Shire (Takeda), and spent over 15 years at Biogen involved in the development and commercialization of Avonex®, Tysabri®, and Tecfidera®. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care, and drug development. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology.

Robert Langer is a Massachusetts Institute of Technology (MIT) professor and an expert in biotechnology and engineering. Dan Anderson is a Massachusetts Institute of Technology (MIT) professor and an expert in nano-based drugs and cancer immunology. Pierre Matussiere has more than twenty years of experience as an investment banker for Société Générale, Citigroup and BNP Paribas, primarily out of London. Kevin McLaughlin is a finance and management executive with more than 40 years of experience in the biopharma and high-tech industries. Robert Ruffolo is the former president of research & development at Wyeth Pharmaceuticals and brings a wealth of experience in drug discovery and development. Paul Wotton is a serial entrepreneur and inventor with more than 30 years of experience in the biotech and pharma industries.

Our Mission: To identify and accelerate promising medicines that revolutionize treatment and quality of life for patients with cancer. We know quality science and leverage our team’s deep knowledge to create a viable product development strategy that supports commercial potential and company growth. Among our most notable projects is the early investment, formation and growth of Biohaven Pharmaceuticals, leading the Company to the second-largest IPO in 2017 and later its successful commercialization leading to acquisition by Pfizer for approximately $12 billion in 2022. Each platform in our pipeline yields multiple products, and those products are discussed with potential big pharma partners and selected for clinical development if they are differentiated and have a compelling product profile. Ian Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and innovation of new therapies for the treatment of severe diseases. Robert has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals, part of the Johnson & Johnson group of companies. Robert has 24 years of experience in the pharmaceutical industry and is the former Head of Oncology Discovery Research at both Bristol-Myers Squibb and Janssen Pharmaceuticals , part of the Johnson & Johnson group of companies. Steve Innaimo is a seasoned R&D expert who brings more than 25 years of experience in drug development from the large pharma, biotech and contract research organization sectors.

Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations. Thierry Abribat is a biotech entrepreneur who has founded and managed three biotech companies, one of which, Alizé Pharma 2, was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) and, another, Alizé Pharma, was acquired by Millendo Therapeutics (Nasdaq: MLND). Mark Sumeray has 23 years of experience across the pharmaceutical, medical devices and biotech industries, both in the US and EU. Thomas Delale is a biopharmaceutical professional with over 18 years of experience that spans from peptide drug discovery to late clinical stage development and corporate/business development. David has a strong experience working with CMO/CRO and developing product with top pharmaceutical or biotechnologies companies in Europe, US, India and China. Benedicte Gagnere has over 20 years experience in leading financial planning, control & accounting functions and reporting on all international operations. Legault also serves as the chairman of Artios Pharma, Bicycle Therapeutics and Poxel Pharma.